Related references
Note: Only part of the references are listed.Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Meletios Dimopoulos et al.
LEUKEMIA (2021)
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
Melissa Alsina et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. A. Dimopoulos et al.
ANNALS OF ONCOLOGY (2021)
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma The MANHATTAN Nonrandomized Clinical Trial
Ola Landgren et al.
JAMA ONCOLOGY (2021)
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
Stefania Oliva et al.
BLOOD CANCER JOURNAL (2021)
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
Joshua D. Hansen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Nizar J. Bahlis et al.
LEUKEMIA (2020)
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees et al.
BLOOD (2020)
First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
Brian G. M. Durie et al.
BLOOD CANCER JOURNAL (2020)
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jagoda K. Jasielec et al.
BLOOD (2020)
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo et al.
LANCET HAEMATOLOGY (2020)
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Niels W. C. J. van de Donk et al.
BLOOD (2020)
Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
Francesca Gay et al.
BLOOD (2020)
Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study
Shaji K. Kumar et al.
BLOOD (2020)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Multiple myeloma: Every year a new standard?
S. Vincent Rajkumar
HEMATOLOGICAL ONCOLOGY (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G. Richardson et al.
LANCET ONCOLOGY (2019)
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Laura Rosinol et al.
BLOOD (2019)
Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)
Sagar Lonial et al.
BLOOD (2019)
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
Manuela Gambella et al.
CANCER (2019)
The teratogenic effects of thalidomide on limbs
Neil Vargesson
JOURNAL OF HAND SURGERY-EUROPEAN VOLUME (2019)
Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016
Jiangmei Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Drew W. Rasco et al.
CLINICAL CANCER RESEARCH (2019)
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
Mary E. Matyskiela et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Amrita Krishnan et al.
LEUKEMIA (2018)
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Laurent Garderet et al.
BLOOD (2018)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Quinlan L. Sievers et al.
SCIENCE (2018)
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project
Saad Z. Usmani et al.
BLOOD CANCER JOURNAL (2018)
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial
Niels W. C. J. van de Donk et al.
LANCET HAEMATOLOGY (2018)
Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus
Peter H. Schafer et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM)
Sheeba K. Thomas et al.
BLOOD (2018)
Iberdomide (CC-220) Has Synergistic Anti Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro
Michael Amatangelo et al.
BLOOD (2018)
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon et al.
BLOOD (2018)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
Rafael Rios-Tamayo et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma
Shahzad Raza et al.
CURRENT CANCER DRUG TARGETS (2017)
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
Meletios A. Dimopoulos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau et al.
ANNALS OF ONCOLOGY (2017)
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Sarah A. Holstein et al.
DRUGS (2017)
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD (2016)
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
Sonja Zweegman et al.
BLOOD (2016)
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
Rachid C. Baz et al.
BLOOD (2016)
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau et al.
BLOOD (2016)
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Takumi Ito et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study
Chiara Dalla Torre et al.
NEUROLOGY (2016)
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Jatin J. Shah et al.
BLOOD (2015)
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma
A. Keith Stewart et al.
BLOOD (2015)
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2015)
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay et al.
LANCET ONCOLOGY (2015)
Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
C. C. Bjorklund et al.
BLOOD CANCER JOURNAL (2015)
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2015)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myelome
Murielle Roussel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs
Philip P. Chamberlain et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Lotfi Benboubker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity
Alexander L. Ruchelman et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
Alessandra Larocca et al.
BLOOD (2013)
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial
A. Keith Stewart et al.
BLOOD (2013)
Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
Gareth J. Morgan et al.
CLINICAL CANCER RESEARCH (2013)
Immunomodulatory Drugs: New Options for the Treatment of Myelodysplastic Syndromes
Roberto Castelli et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
A. A. Chanan-Khan et al.
BLOOD CANCER JOURNAL (2013)
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
Gareth J. Morgan et al.
BLOOD (2012)
IMWG consensus on maintenance therapy in multiple myeloma
Heinz Ludwig et al.
BLOOD (2012)
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
Shaji Kumar et al.
BLOOD (2012)
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
Michele Cavo et al.
BLOOD (2012)
Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses
Kimberly Noonan et al.
CLINICAL CANCER RESEARCH (2012)
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial
Martin Kropff et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Management of treatment-emergent peripheral neuropathy in multiple myeloma
P. G. Richardson et al.
LEUKEMIA (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
Peter M. Fayers et al.
BLOOD (2011)
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
Meral Beksac et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
The Ikaros gene family: Transcriptional regulators of hematopoiesis and immunity
Liza B. John et al.
MOLECULAR IMMUNOLOGY (2011)
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Henk M. Lokhorst et al.
BLOOD (2010)
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Anders Waage et al.
BLOOD (2010)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Lenalidomide mode of action: linking bench and clinical findings
Faith Davies et al.
BLOOD REVIEWS (2010)
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
Pierre Wijermans et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H. Quach et al.
LEUKEMIA (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Cyrille Hulin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo et al.
BLOOD (2008)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo et al.
BLOOD (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Thalidomide analogues as anticancer drugs
Jeanny B. Aragon-Ching et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2007)
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
A Glasmacher et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
SV Rajkumar et al.
CANCER TREATMENT REVIEWS (2000)
Share Paper
